Oxford BioMedica Plc (OXB):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Oxford BioMedica Plc (OXB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10092
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:73
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oxford BioMedica plc (Oxford Biomedica) is a gene and cell therapy company that focuses on developing novel treatments for serious diseases. The company along with its subsidiaries has developed LentiVector, a sector leading lentiviral vector delivery platform. It has also built a platform of special cutting-edge technologies and capabilities, based on LentiVector. Based on LentiVector delivery platform Oxford BioMedica has developed a portfolio of gene and cell therapy product candidates in cancer, ophthalmology and central nervous system (CNS) therapy areas. The company also provides lentiviral vector bioprocessing and process development services to partners. Oxford BioMedica is headquartered Oxford, the UK.

Oxford BioMedica Plc (OXB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oxford BioMedica Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Oxford BioMedica Plc, Medical Devices Deals, 2012 to YTD 2018 10
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Oxford BioMedica Acquires Windrush Court Office and Laboratory Facilities for USD5 Million 13
Partnerships 14
Boehringer Ingelheim, Imperial College London, University of Oxford, University of Edinburgh, Imperial Innovations, and Oxford BioMedica Enter into Collaboration Agreement 14
Oxford BioMedica Enters into Agreement with Cell Therapy Catapult, Stratophase and Synthace 16
Oxford BioMedica Enters into Agreement with Novartis 17
Oxford BioMedica Enters into Agreement with Green Cross 18
Oxford BioMedica Enters into Agreement with Novartis 19
Licensing Agreements 20
Axovant Sciences Enters into Licensing Agreement with Oxford BioMedica 20
Bioverativ Enters into Licensing Agreement with Oxford BioMedica 22
Orchard Therapeutics Expands Licensing Agreement with Oxford BioMedica 23
Oxford BioMedica Exercises Option for Licensing Agreement with GlaxoSmithKline 24
Oxford BioMedica Enters into Licensing Agreement with Novartis for LentiVector 25
Oxford BioMedica Amends Licensing Agreement With Sanofi 26
Oxford BioMedica Enters into Licensing Agreement with MolMed 27
Immune Design Licensing Agreement with Oxford BioMedica 28
Equity Offering 29
Oxford BioMedica to Raise USD28.4 Million in Private Placement of Shares 29
Oxford BioMedica Raises USD15.3 Million in Private Placement of Shares 30
Oxford BioMedica to Raise USD11.5 Million in Private Placement of Shares 32
Oxford BioMedica Raises USD33 Million in Private Placement of Shares 34
Oxford BioMedica Raises USD2.6 Million in Public Offering 36
Oxford BioMedica Completes Private Placement Of Shares For US$17 Million 37
Oxford BioMedica Completes Rights Offering Of Shares For US$1 Million 38
Oxford BioMedica Plc – Key Competitors 39
Oxford BioMedica Plc – Key Employees 40
Oxford BioMedica Plc – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Strategy And Business Planning 42
Sep 13, 2018: Oxford Biomedica announces further capacity expansion with new facility 42
Financial Announcements 43
Sep 13, 2018: Oxford Biomedica interim results for the six months ended 30 June 2018 43
Mar 15, 2018: Oxford Biomedica: Preliminary Results for the Year Ended 31 December 2017 49
Aug 17, 2017: Oxford Biomedica: Interim Results For The Six Months Ended 30 June 2017 59
Mar 16, 2017: Oxford Biomedica Announces Preliminary Results for the Year Ended 31 December 2016 64
Corporate Communications 65
Jul 02, 2018: Oxford BioMedica Announces Directorate Change 65
Jun 04, 2018: Oxford BioMedica Announces Directorate Change 66
Mar 15, 2018: Board Change: Oxford BioMedica Appoints Heather Preston as Non-Executive Director 67
Aug 29, 2017: Oxford BioMedica: Stuart Paynter starts as new Chief Financial Officer 68
Feb 28, 2017: Oxford BioMedica Appoints New Chief Financial Officer 69
Government and Public Interest 70
Jan 23, 2018: Oxford BioMedica announces £3 million grant awarded by Innovate UK 70
Other Significant Developments 71
Mar 28, 2018: Gyros Protein Technologies installs two Gyrolab xPlore systems at Oxford BioMedica for gene and cell therapy applications 71
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73

List of Tables
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oxford BioMedica Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oxford BioMedica Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Oxford BioMedica Plc, Medical Devices Deals, 2012 to YTD 2018 10
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Oxford BioMedica Acquires Windrush Court Office and Laboratory Facilities for USD5 Million 13
Boehringer Ingelheim, Imperial College London, University of Oxford, University of Edinburgh, Imperial Innovations, and Oxford BioMedica Enter into Collaboration Agreement 14
Oxford BioMedica Enters into Agreement with Cell Therapy Catapult, Stratophase and Synthace 16
Oxford BioMedica Enters into Agreement with Novartis 17
Oxford BioMedica Enters into Agreement with Green Cross 18
Oxford BioMedica Enters into Agreement with Novartis 19
Axovant Sciences Enters into Licensing Agreement with Oxford BioMedica 20
Bioverativ Enters into Licensing Agreement with Oxford BioMedica 22
Orchard Therapeutics Expands Licensing Agreement with Oxford BioMedica 23
Oxford BioMedica Exercises Option for Licensing Agreement with GlaxoSmithKline 24
Oxford BioMedica Enters into Licensing Agreement with Novartis for LentiVector 25
Oxford BioMedica Amends Licensing Agreement With Sanofi 26
Oxford BioMedica Enters into Licensing Agreement with MolMed 27
Immune Design Licensing Agreement with Oxford BioMedica 28
Oxford BioMedica to Raise USD28.4 Million in Private Placement of Shares 29
Oxford BioMedica Raises USD15.3 Million in Private Placement of Shares 30
Oxford BioMedica to Raise USD11.5 Million in Private Placement of Shares 32
Oxford BioMedica Raises USD33 Million in Private Placement of Shares 34
Oxford BioMedica Raises USD2.6 Million in Public Offering 36
Oxford BioMedica Completes Private Placement Of Shares For US$17 Million 37
Oxford BioMedica Completes Rights Offering Of Shares For US$1 Million 38
Oxford BioMedica Plc, Key Competitors 39
Oxford BioMedica Plc, Key Employees 40
Oxford BioMedica Plc, Other Locations 41
Oxford BioMedica Plc, Subsidiaries 41

List of Figures
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Oxford BioMedica Plc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Oxford BioMedica Plc (OXB):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bajaj Finance Ltd (BAJFINANCE):企業の財務・戦略的SWOT分析
    Bajaj Finance Ltd (BAJFINANCE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Heidelberg Pharma AG (WL6)-製薬・医療分野:企業M&A・提携分析
    Summary Heidelberg Pharma AG(Heidelberg Pharma) formerly known as Wilex AG is a biopharmaceutical company with a focus on cancer. The company develops therapeutic and diagnostic product candidates for the treatment and specific detection of various cancers. It develops products based on and small mo …
  • Viterra Inc.:企業の戦略・SWOT・財務情報
    Viterra Inc. - Strategy, SWOT and Corporate Finance Report Summary Viterra Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Nanosonics Ltd (NAN)-医療機器分野:企業M&A・提携分析
    Summary Nanosonics Ltd (Nanosonics) is a medical technology company, which focuses on the development of technologies for infection control. Its product portfolio includes decontamination products and accessories for the prevention of hospital acquired infections (HAI). The company’s trophon EPR is …
  • Invetech Pty Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Invetech Pty Ltd (Invetech), a subsidiary of Danaher Corp is a manufacturer of custom automation systems. The company offers services which include product development, instrument development, custom automation and contract manufacturing. It specializes in applied sciences, automated measure …
  • Toshiba Semiconductor Company:企業の戦略的SWOT分析
    Toshiba Semiconductor Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • ams AG (AMS):企業の財務・戦略的SWOT分析
    Summary ams AG (ams), formerly austriamicrosystems AG is a technology company that manufactures and markets semiconductor products. The company's products comprise audio systems, environmental sensors, light sensors, smart light management, spectral sensing, CMOS imaging sensors, medical imaging and …
  • Western Power Distribution Plc:企業の戦略的SWOT分析
    Western Power Distribution Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Cochin Shipyard Ltd (COCHINSHIP):企業の財務・戦略的SWOT分析
    Cochin Shipyard Ltd (COCHINSHIP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Airasia Group Berhad:企業の戦略・SWOT・財務分析
    Airasia Group Berhad - Strategy, SWOT and Corporate Finance Report Summary Airasia Group Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • BOE Technology Group Co Ltd:戦略・SWOT・企業財務分析
    BOE Technology Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary BOE Technology Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Oryzon Genomics SA (ORY):企業の財務・戦略的SWOT分析
    Summary Oryzon Genomics SA (Oryzon) is a clinical stage biopharmaceutical company that offers discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. The company offers epigenetics, a regulatory system that controls gene expression without affecting the makeup o …
  • State Bank of India:企業のM&A・事業提携・投資動向
    State Bank of India - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's State Bank of India Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Kaefer Isoliertechnik GmbH & Co KG:企業の戦略・SWOT・財務情報
    Kaefer Isoliertechnik GmbH & Co KG - Strategy, SWOT and Corporate Finance Report Summary Kaefer Isoliertechnik GmbH & Co KG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Genmedica Therapeutics SL-製薬・医療分野:企業M&A・提携分析
    Summary Genmedica Therapeutics SL (Genmedica) is a clinical-stage biopharmaceutical company that researches, discovers and develops orally available NCEs for the treatment of diabetes. The company’s expertise spans in the development of specific, dual-action, small molecule inhibitors that targets b …
  • Hainan Airlines Co Ltd:企業の戦略・SWOT・財務分析
    Hainan Airlines Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Hainan Airlines Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Genextra Spa-製薬・医療分野:企業M&A・提携分析
    Summary Genextra SpA (Genextra) is a pharmaceutical company that discovers and develops therapies for age-related and metabolic diseases. The company develops INT-747 for comb, mono therapy and diabetes, INT- 777 for metabolic syndrome; novel HDAC and HSP90 inhibitors for the treatment of cancer; mj …
  • Memry Corp:企業の戦略的SWOT分析
    Memry Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Societe Des Bains De Mer Sa
    Societe Des Bains De Mer Sa - Strategy, SWOT and Corporate Finance Report Summary Societe Des Bains De Mer Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Antilles Oil and Gas NL (AVD):石油・ガス:M&Aディール及び事業提携情報
    Summary Antilles Oil and Gas NL (Antilles) is an upstream oil and gas company that carries out the acquisition and exploration of petroleum and gas properties. The company acquires underperforming assets and re-evaluates to identify untapped recoverable reserves. The company’s operates an exploratio …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆